The Next Frontier: The Promise Of Immunotherapy In Gastrointestinal Cancers

By Arlene Weintraub | Cure

gut intestines

Mary Ann Machol was 44 in 2013 when she learned she had inoperable stage 4 colorectal cancer — a difficult diagnosis that left her with no choice but to undergo the harsh three-drug chemotherapy regimen known as FOLFOX. The cocktail (consisting of leucovorin, fluorouracil and oxaliplatin) helped shrink her tumors, but then she was diagnosed with uterine cancer, and had to stop all treatments. After undergoing surgery to remove her uterus, Machol, who lives in the San Francisco Bay area, was put on a different chemotherapy regimen for the colorectal cancer.

By the end of 2014, Machol had run out of options. Then she learned about a trial at Stanford University involving a drug that stimulates the immune system to fight off cancer. The drug, Keytruda (pembrolizumab), from Merck, was already on the market and being used successfully in melanoma and certain lung cancer patients. In March 2015, Machol was accepted into the trial and began receiving infusions of Keytruda every two weeks.

Related Article: Immunotherapy Is The Future Of Cancer Research: 70% Of Multiple Myeloma Patients Find Recovery With New Treatment

“After the second dose, I started feeling better,” Machol says. “I had been in severe pain — on high doses of morphine around the clock, bedridden and sleeping 16 to 20 hours a day. Then, all of a sudden, I was cutting back on the morphine. I was down to about 100 pounds because I couldn’t eat, but by summer I had gained all my weight back.” Machol’s tumors are shrinking, classifying her as a partial responder to the drug so far. She will remain in the trial through 2017.

Keytruda is among an emerging class of drugs that block “checkpoints” in the body that prevent the immune system from being able to recognize and eradicate cancer cells. Keytruda specifically targets the checkpoint PD-1, which has emerged as an important target in several types of gastrointestinal (GI) cancers, including colorectal, gastric and esophageal cancers.

“GI malignancies are the next frontier for immunotherapy,” says Yelena Janjigian, a medical oncologist at Memorial Sloan Kettering Cancer Center in New York who has been an investigator for several immunotherapy trials. “Several patients of mine with metastatic stomach cancer have failed every standard treatment and have had dramatic and durable responses to immunotherapy. It really has changed lives.”

Tags: , , , , , , ,

Subscribe

If you enjoyed this article, subscribe now to receive more just like it.

Subscribe via RSS Feed Connect on YouTube

3 Reader Comments

Trackback URL Comments RSS Feed

  1. 1695510010723187@facebook.com' Cương Lưu says:

    Hi everybody, Conscious Life News…Only 3% of people can answer these questions,…
    K8VmDb1 play now (y) ~> http://goo.gl/Qh3ScN

    Thanks for view: Dramatic and durable responses to immunotherapy has changed lives for patients who have failed every standard treatment….

  2. 10204415753352334@facebook.com' Sally Navarro Merdian says:

    Scott N Sharee

New Title

NOTE: Email is optional. Do NOT enter it if you do NOT want it displayed.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

FAIR USE NOTICE. Many of the articles on this site contain copyrighted material whose use has not been specifically authorized by the copyright owner. We are making this material available in an effort to advance the understanding of environmental issues, human rights, economic and political democracy, and issues of social justice. We believe this constitutes a 'fair use' of the copyrighted material as provided for in Section 107 of the US Copyright Law which contains a list of the various purposes for which the reproduction of a particular work may be considered fair, such as criticism, comment, news reporting, teaching, scholarship, and research. If you wish to use such copyrighted material for purposes of your own that go beyond 'fair use'...you must obtain permission from the copyright owner. And, if you are a copyright owner who wishes to have your content removed, let us know via the "Contact Us" link at the top of the site, and we will promptly remove it.

The information on this site is provided for educational and entertainment purposes only. It is not intended as a substitute for professional advice of any kind. Conscious Life News assumes no responsibility for the use or misuse of this material. Your use of this website indicates your agreement to these terms.

Paid advertising on Conscious Life News may not represent the views and opinions of this website and its contributors. No endorsement of products and services advertised is either expressed or implied.
Top

Send this to a friend